Wall Street analysts forecast that Puma Biotechnology Inc (NASDAQ:PBYI) will announce earnings of ($0.48) per share for the current quarter, according to Zacks. Three analysts have made estimates for Puma Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.59). Puma Biotechnology posted earnings of ($0.80) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 40%. The firm is expected to announce its next earnings report on Thursday, February 27th.
On average, analysts expect that Puma Biotechnology will report full-year earnings of ($2.14) per share for the current fiscal year, with EPS estimates ranging from ($2.26) to ($2.08). For the next financial year, analysts expect that the company will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.29) to ($0.95). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.32. The company had revenue of $56.40 million for the quarter, compared to the consensus estimate of $60.21 million. Puma Biotechnology had a negative net margin of 33.90% and a negative return on equity of 325.89%. Puma Biotechnology’s revenue was down 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 earnings per share.
Puma Biotechnology stock traded up $0.34 during mid-day trading on Wednesday, reaching $8.75. 1,270,333 shares of the company’s stock traded hands, compared to its average volume of 1,896,956. The company has a market cap of $340.90 million, a price-to-earnings ratio of -2.93 and a beta of 1.69. The stock has a 50 day moving average of $8.76 and a two-hundred day moving average of $9.87. The company has a quick ratio of 1.67, a current ratio of 1.71 and a debt-to-equity ratio of 6.84. Puma Biotechnology has a 12-month low of $6.26 and a 12-month high of $43.90.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Swiss National Bank raised its stake in shares of Puma Biotechnology by 2.0% in the second quarter. Swiss National Bank now owns 56,730 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 1,100 shares during the period. Metropolitan Life Insurance Co NY increased its stake in Puma Biotechnology by 14.0% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 10,615 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,305 shares during the period. Northern Trust Corp increased its stake in Puma Biotechnology by 0.4% in the 2nd quarter. Northern Trust Corp now owns 356,356 shares of the biopharmaceutical company’s stock worth $4,530,000 after buying an additional 1,477 shares during the period. Bank of Montreal Can increased its stake in Puma Biotechnology by 577.6% in the 2nd quarter. Bank of Montreal Can now owns 2,602 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 2,218 shares during the period. Finally, BB&T Securities LLC increased its stake in Puma Biotechnology by 22.9% in the 2nd quarter. BB&T Securities LLC now owns 13,397 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 2,499 shares during the period. 92.70% of the stock is currently owned by institutional investors and hedge funds.
About Puma Biotechnology
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).
See Also: Profit Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.